Seidmon E J, Krisch E B, Truant A L, Amy B G, Childs S J, Hurst A T, McCabe R E
Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania.
Urology. 1990 Feb;35(2):187-93. doi: 10.1016/0090-4295(90)80074-w.
Norfloxacin, a broad-spectrum antimicrobial analog of nalidixic acid, was evaluated by comparing it to trimethoprim-sulfamethoxazole in 93 office patients with recurrent urinary tract infections. In this prospective randomized study, norfloxacin and trimethoprim-sulfamethoxazole were given on the same dosage schedule with the former drug given as a 400-mg tablet twice daily and the latter drug given as a double strength tablet twice daily. Overall, 50 patients received norfloxacin and 43 patients received trimethoprim-sulfamethoxazole with a cure rate of 96 percent and 79 percent, respectively. Whether a patient had one infection or multiple previous infections, norfloxacin appeared to be superior to trimethoprim-sulfamethoxazole. Only minor side effects were noted in either group, and no patient withdrew from this study as a direct result of these side effects. Minor complaints of nausea, dizziness, and headache were found in the norfloxacin group (24%) and in the trimethoprim-sulfamethoxazole group (16%). Both agents are effective in treating urinary tract infections but norfloxacin is superior to trimethoprim-sulfamethoxazole in patients with either recurrent complicated infections or one previous uncomplicated urinary tract infection.
诺氟沙星是萘啶酸的一种广谱抗菌类似物，通过将其与甲氧苄啶-磺胺甲恶唑对比，对93例复发性尿路感染的门诊患者进行了评估。在这项前瞻性随机研究中，诺氟沙星和甲氧苄啶-磺胺甲恶唑采用相同的给药方案，前者给予400毫克片剂，每日两次，后者给予双倍剂量片剂，每日两次。总体而言，50例患者接受了诺氟沙星治疗，43例患者接受了甲氧苄啶-磺胺甲恶唑治疗，治愈率分别为96%和79%。无论患者是单次感染还是既往有多次感染，诺氟沙星似乎都优于甲氧苄啶-磺胺甲恶唑。两组均仅出现轻微副作用，且没有患者因这些副作用而直接退出本研究。诺氟沙星组（24%）和甲氧苄啶-磺胺甲恶唑组（16%）均出现了轻微的恶心、头晕和头痛主诉。两种药物都对治疗尿路感染有效，但在复发性复杂感染或既往有一次单纯性尿路感染的患者中，诺氟沙星优于甲氧苄啶-磺胺甲恶唑。
